Rallybio (RLYB)
NASDAQ:RLYB
RLYB Stock Chart & Stats
$9.11
-$0.04(-3.69%)
At close: 4:00 PM EST
$9.11
-$0.04(-3.69%)
Day’s Range― - ―
52-Week Range$1.76 - $11.49
Previous CloseN/A
Volume36.64K
Average Volume (3M)283.42K
Market Cap
$47.45M
Enterprise Value$13.24M
Total Cash (Recent Filing)$54.74M
Total Debt (Recent Filing)$176.00K
Price to Earnings (P/E)―
Beta0.97
Next Earnings
May 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding5,289,675
10 Day Avg. Volume220,035
30 Day Avg. Volume283,421
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.53
Price to Sales (P/S)36.02
P/FCF Ratio-1.04
Enterprise Value/Market Cap0.28
Enterprise Value/Revenue15.43
Enterprise Value/Gross Profit15.48
Enterprise Value/Ebitda-0.40
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-7.8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial StrategyThe recent workforce reduction plan and sale of REV102 interest should provide cash runway into mid-2027.
Pipeline DevelopmentRallybio will now focus its resources on advancing other pipeline programs, notably RLYB116, an inhibitor of complement component 5 (C5) with potential applications in treating complement-related diseases.
Regulatory ApprovalPh2 Study Of '212 In Pregnant Women At Higher Risk For FNAIT received green lights from EU's EMA and UK's MHRA, allowing the start of the trial.
Bears Say
Clinical Trial SetbacksRLYB212 failed to meet the minimum target PK concentration and there is not enough data to accurately dose adjust safely.
EarningsRLYB reported a 2Q25 net loss of $9.7M.
Program DiscontinuationRallybio has announced the discontinuation of its RLYB212 program, which was undergoing development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Rallybio News
RLYB FAQ
What was Rallybio’s price range in the past 12 months?
Rallybio lowest stock price was $1.76 and its highest was $11.49 in the past 12 months.
What is Rallybio’s market cap?
Rallybio’s market cap is $47.45M.
When is Rallybio’s upcoming earnings report date?
Rallybio’s upcoming earnings report date is May 12, 2026 which is in 40 days.
How were Rallybio’s earnings last quarter?
Rallybio released its earnings results on Mar 17, 2026. The company reported -$1.24 earnings per share for the quarter, the consensus estimate of -$1.24 by $0.
Is Rallybio overvalued?
According to Wall Street analysts Rallybio’s price is currently Overvalued.
Does Rallybio pay dividends?
Rallybio does not currently pay dividends.
What is Rallybio’s EPS estimate?
Rallybio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rallybio have?
Rallybio has 5,289,675 shares outstanding.
What happened to Rallybio’s price movement after its last earnings report?
Rallybio reported an EPS of -$1.24 in its last earnings report, expectations of -$1.24. Following the earnings report the stock price went up 2.55%.
Which hedge fund is a major shareholder of Rallybio?
Currently, no hedge funds are holding shares in RLYB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rallybio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Sold Shares
Worth $4.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 4.4%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-50.80%
12-Months-Change
Fundamentals
Return on Equity
-16.25%
Trailing 12-Months
Asset Growth
-8.58%
Trailing 12-Months
Company Description
Rallybio
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
Technical Analysis
Moleculin Biotech
―
Aptevo Therapeutics
―
Citius Pharmaceuticals
―
Processa Pharmaceuticals
―
Allarity Therapeutics
―